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Abstract
Following a successful renal transplantation circulating markers of inflammation may remain
elevated, and systemic inflammation is associated with worse clinical outcome in renal
transplant recipients (RTRs). Vitamin D-receptor (VDR) activation is postulated to modulate
inflammation and endothelial function. We aimed to explore if a synthetic vitamin D, parical-
citol, could influence systemic inflammation and immune activation in RTRs. Newly trans-
planted RTRs were included in an open-label randomized controlled trial on the effect of
paricalcitol on top of standard care over the first post-transplant year. Fourteen pre-defined
circulating biomarkers reflecting leukocyte activation, endothelial activation, fibrosis and
general inflammatory burden were analyzed in 74 RTRs at 8 weeks (baseline) and 1 year
post-engraftment. Mean changes in plasma biomarker concentrations were compared by t-
test. The expression of genes coding for the same biomarkers were investigated in 1-year
surveillance graft biopsies (n = 60). In patients treated with paricalcitol circulating osteopro-
tegerin levels increased by 0.19 ng/ml, compared with a 0.05 ng/ml increase in controls (p =
0.030). In graft tissue, a 21% higher median gene expression level of TNFRSF11B coding
for osteoprotegerin was found in paricalcitol-treated patients compared with controls (p =
0.026). Paricalcitol treatment did not significantly affect the blood- or tissue levels of any
other investigated inflammatory marker. In RTRs, paricalcitol treatment might increase both
circulating and tissue levels of osteoprotegerin, a modulator of calcification, but potential
anti-inflammatory treatment effects in RTRs are likely very modest.
[NCT01694160 (2012/107D)]; [www.clinicaltrials.gov].
PLOS ONE







Citation: Pihlstrøm HK, Ueland T, Michelsen AE,
Aukrust P, Gatti F, Hammarström C, et al. (2020)
Exploring the potential effect of paricalcitol on
markers of inflammation in de novo renal
transplant recipients. PLoS ONE 15(12): e0243759.
https://doi.org/10.1371/journal.pone.0243759
Editor: Frank JMF Dor, Imperial College Healthcare
NHS Trust, UNITED KINGDOM
Received: June 16, 2020
Accepted: November 29, 2020
Published: December 16, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0243759
Copyright: © 2020 Pihlstrøm et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Norwegian Data
Protection Authorities have a strict practice
concerning access to research data. Access to data
collected from this study, including de-identified
Introduction
Chronic kidney disease (CKD) is associated with systemic inflammation. In end-stage renal dis-
ease there is a strong association between inflammation marker C-reactive protein (CRP) and
risk of death and cardiovascular events [1]. Increased oxidative stress, the accumulation of toxic
metabolites (e.g. microbiota-dependent amine oxides) and chronic activation of various cell
subsets of both the innate and adaptive immune system creates a pro-inflammatory milieu in
CKD [2, 3]. Following a successful renal transplantation with appropriate immunosuppression
obtained by a combination of drugs, both endothelial dysfunction and low-grade inflammation
is ameliorated by reversal of the uremic state [4, 5], while the lipid oxidative state seems more
refractory [6]. Some derangements in immune function will however persist [7, 8], especially if
graft function is sub-optimal. Even among renal transplant recipients (RTRs) with low Fra-
mingham risk scores, implying a limited burden of comorbidity, there is evidence for enhanced
systemic inflammation [9]. In stable RTRs, interleukin-6 (IL-6) and CRP, has been associated
with risk of major cardiovascular events and all-cause mortality [10], as has neopterin [11, 12], a
marker of interferon (IFN) γ-mediated activation of monocytes/macrophages.
Vitamin D is a fat-soluble vitamin central to the maintenance of bone- and mineral homeo-
stasis. Poor vitamin D status has also been associated with increased risk of cancer [13], infec-
tions [14, 15], autoimmune diseases [16], cardiovascular events [17], obesity [18] and diabetes
[19]. However, interventional studies on vitamin D supplementation report equivocal and
inconsistent effects on non-skeletal clinical outcomes, and larger randomized controlled trials
are ongoing [20–22]. Anti-inflammatory and immune-modulating effects of vitamin D -sup-
plements could be of particular benefit for renal transplant patients, as they are prone to vita-
min D-deficiency, while at the same time carrying an increased risk of all of the above
mentioned chronic conditions [23, 24].
Paricalcitol (19-nor-1,25-dihydroxyvitamin D2), a synthetic selective third generation vita-
min D-receptor agonist (VDRA), is used in patients with CKD to treat secondary hyperparathy-
roidism. Potential non-skeletal benefits of paricalcitol include anti-proteinuric effects in
patients with diabetes [25] and in RTRs [26]. VDRAs seem also to have anti-inflammatory
potential, and experimental studies have indicated dampened tumor necrosis factor (TNF) and
interleukin-8 (IL-8) production [27] and reduced inflammation and fibrosis development [28].
An observational study in RTRs with secondary hyperparathyroidism found that 3 months
of treatment with paricalcitol reduced serum IL-6 and TNF levels, with corresponding lowered
mRNA expression in peripheral blood mononuclear cells [29]. In a clinical trial of 168 RTRs
with proteinuria, paricalcitol treatment on top of RAAS-blockade caused significant reduc-
tions in circulating IL-6 and the pro-fibrotic mediator transforming growth factor beta (TGF-
β) [30]. We were, however, not able to demonstrate a treatment effect of paricalcitol on high
sensitity (hs) CRP in 77 newly transplanted RTRs [31], but it is unlikely that hsCRP reflects all
inflammatory pathways that are activated in RTRs.
Cytokines and inflammatory molecules are operating in a complex network, and our aim in
the current study on renal transplant recipients was to explore the potential effect of paricalcitol
on a broader range of pre-defined circulating inflammatory markers, including markers reflecting
leukocyte activation, endothelial activation, fibrosis and more general vascular inflammation.
Materials and methods
Study design
From Jan 2013 up until Jan 2014, 77 patients >18 years of age who had received a kidney
transplant or a combined kidney-pancreas transplant were randomized to receive either
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treatment with paricalcitol 2 μg daily or standard post-transplant care. Study randomization
and baseline laboratory measurements took place 7–8 weeks after transplantation. The last
study visit was scheduled one year after date of engraftment and included repeated blood sam-
pling and collection of renal transplant biopsy tissue for subsequent histopathology evaluation
and RNA extraction. To be eligible for the study, patients should have an estimated glomerular
filtration rate (eGFR) by the CKD-EPI formula of at least 30 ml/min, total serum calcium levels
should range between 2.0 and 2.6 mmol/l, and the immunosuppressive regimen should
include a calcineurin inhibitor (CNI). Patients already undergoing treatment with vitamin D,
VDRA or calcimimetic drugs were excluded, as were patients with established osteoporosis in
the axial skeleton, patient with a history of hypersensitivity towards paricalcitol or related
drugs and recipients receiving organs from a donor older than 75 years. Results concerning
the primary endpoint (potential anti-proteinuric effect) and main secondary endpoints are
found elsewhere [31], as is the Consort diagram presenting the screening- and inclusion pro-
cess. In short, both the baseline- and 1-year visits consisted of the following investigations:
Blood samples for routine biochemistry and frozen storage, spot urine albumin/creatinine
ratio, pulse wave velocity measurements, assessment of endothelial function by a noninvasive
plethysmographic method, allograft protocol biopsy with collection of tissue for RNA extrac-
tion and measured glomerular filtration rate (mGFR) by iohexol clearance. All patients pro-
vided written informed consent before inclusion in the trial. The study conformed to the
principles of the Declaration of Helsinki and the Declaration of Istanbul. The study protocol
was approved by the Regional Ethics Committee, officially known as REK South East (study
no 2012/107) and the hospital´s Research Administration (The Oslo University Hospital Data
Protection Authority as well as the Radiology Research Administration, FU-ARN). It was also
approved by the Norwegian Medicines Agency, SLV (Eudract no: 2012-000429-32). The
Department of Organ Transplantation at Oslo University Hospital was responsible for the
coordination and conduction of the trial.
Outcomes
Cytokines and inflammatory molecules are operating in a complex network, and our aim in
the current study was to explore the potential effect of paricalcitol on a broader range of stable
and readily measurable circulating inflammatory markers. We included biomarkers reflecting
leukocyte activation (neopterin, soluble CD14 and soluble CD163 as markers of monocyte/
macrophage activation; neutrophil gelatinase-associated lipocalin [NGAL] as a marker of neu-
trophil activation), endothelial activation (von Willebrand factor [vWf], and angiopoietin-2),
fibrosis (endostatin, matrix metalloprotease-9 [MMP-9], galectin3, tissue inhibitor of metallo-
proteinase 1 [TIMP-1], activin A) and more general vascular inflammation (osteoprotegerin
[OPG]), soluble tumor necrosis factor-receptor 1 [TNFR 1] and delta like canonical Notch
ligand 1 [DLL1]). As a supplementary analysis the levels of mRNA reflecting expression of
genes coding for the same biomarkers were investigated in renal graft tissue at study end.
Laboratory
After an overnight fast, blood samples were drawn in the morning at the baseline visit and at
the last study visit one year after transplantation. After centrifugation at 2350 g for 10 minutes,
plasma and serum were immediately frozen and samples stored at -72˚ C until analysis (April-
May 2018). Plasma levels of inflammatory markers were measured in duplicate by enzyme
immunoassay (EIA) using R&D Systems (Stillwater, Minneapolis, MN) antibody pairs: Angio-
poietin-2 (DY623), sCD14 (DY383), sCD163 (DY1607), DLL1 (DY1818), Endostatin
(DY1098), MMP9 (DY911), sTNFr1(DY225), Galectin-3 (DY1154), NGAL (DY1757),
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ActivinA (DY338), OPG (DY805), TIMP-1 (DY970). For von Willebrand factor (VWF) the
EIA was performed with antibodies (A0082, P0226) from DakoCytomation (Glostrup, Den-
mark) and for Neopterin, a kit (RE59321) from IBL International GmbH (Hamburg, Ger-
many. Assays were performed in a 384-format using the combination of a SELMA (Jena,
Germany) pipetting robot and a BioTek (Winooski, VT) dispenser/washer (EL406). Primary
and secondary antibody concentrations were used according to manufacturer instructions
(Coating 1–4 μg/ml; secondary 0.2–2 μg/ml). Assay volume was 20 μl and coating was per-
formed in phosphate buffered saline. Subsequent assay buffer was with 1% bovine serum albu-
min in PBS while sample diluent was PBS with 25% heat inactivated fetal calf serum (Gibco,
Thermo Fisher Scientific, Waltham, MA). Wash buffer was PBS with 0.05% tween-20 and
three wash cycles were included per step. Samples were incubated overnight at 4˚C. Absorp-
tion was read at 450 nm with wavelength correction set to 540 nm using an EIA plate reader
(Synergy H1 Hybrid, Biotek, Winooski, VT). Intra- and interassay coefficients of variation
were<10% for all assays. The assays included a series of known concentrations to generate
standard curves.
Gene expression analyses
The procedure of RNA extraction from retrieved transplant biopsy tissue stored in RNAla-
ter1 solution, together with RNA quality assessment, amplification- and labelling procedures
are described elsewhere [31]. Sixty samples, equally divided between study groups, were found
to have sufficient quality for microarray gene expression analyses. For this post-hoc investiga-
tion, we selected 15 gene products reflecting the expression of 13 biomarker proteins. (Neop-
terin is a degradation product for which the circulating level is unlikely to be directly reflected
by the expression any gene).
Statistical methods
The intention-to-treat population consisted of any patient who was randomized and, if
assigned to the treatment group, received at least one dose of study drug, irrespective of any
study protocol violation. The per-protocol population consisted of participants actually fulfill-
ing the protocol requirements for eligibility, intervention and outcome assessment.
Comparisons of baseline variables between study groups were done using t-test, Mann-
Whitney U Test or Pearson χ2 as found appropriate. The potential correlation between change
in osteoprotegerin and change in PTH was tested using Pearsons Correlation test.
The levels of biomarkers in the circulation, expressed as change from baseline to study end,
showed only marginal deviations from a normal distribution, rendering the t-test for indepen-
dent observations applicable. As a sensitivity analysis, ANCOVA was performed, analyzing
group differences in levels of biomarkers at study end with adjustments for baseline levels.
For analyses of microarray data, gene expression levels were log transformed, and normal-
ized intensities were converted to Z-scores, which were used to identify differentially expressed
genes between the paricalcitol group and controls. For each gene, a relative ratio of the mean
Z-scores between the two groups was computed, and the statistical significance of relative
ratios (P-value) was estimated by the two-sample Kolmogorov-Smirnov goodness-of-fit
hypothesis test (KS-test), which does not have a prior assumption for the distribution of gene
expression [32].
Statistical analyses of circulating biomarker levels were performed in SPSS version 21 (IBM,
New York, USA). Microarray gene expression data analysis were performed by either
MATLAB statistics toolbox (MathWorks, Natick, USA) or in-house script files such as Python
based on previously published works [33].
PLOS ONE Effect of paricalcitol on inflammatory pathways in renal transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0243759 December 16, 2020 4 / 14
Results
Baseline characteristics
A total of 74 patients had available plasma samples for analyses of circulating biomarkers at
baseline and study end. Baseline demographics, as well as relevant laboratory values and vital
signs are presented for both study groups in Table 1. There were no statistically significant dif-
ferences between groups, but there was a trend towards more males (Pearson χ2, p = 0.19) and
Table 1. Baseline characteristics of the study populationa.
Variables Paricalcitol Control
(n = 35) (n = 39)
Age, years 55.6 (13.3) 55.1 (12.6)
Male gender 26 (74%) 33 (85%)
Caucasian ethnicity 34 (97%) 37 (95%)
BMI, kg/m2 26.2 (3.3) 25.5 (3.9)
Current smoking 5 (14%) 5 (13%)
Living donor 10 (29%) 12 (31%)
Cold ischemia time, hours 10.4 (6.4) 10.1 (5.7)
Glomerulonephritis as cause of CKD 13 (37.1) 15 (38.5)
Predialytic 13 (37%) 13 (33%)
Hypertension 29 (83%) 36 (92%)
Chronic heart disease 11 (31%) 13 (33%)
Pre-tx diabetes mellitus 6 (17%) 6 (15%)
Systolic blood pressure, mmHg 145 (21) 143 (22)
Diastolic blood pressure, mmHg 83 (10) 84 (11)
Treatment with ACEi/ARB, % 9 (26%) 14 (36%)
Cholesterol, mmol/L 5.8 (1.1) 5.9 (0.9)
HDL cholesterol, mmol/L 1.6 (0.5) 1.6 (0.4)
LDL cholesterol, mmol/L 3.8 (1.0) 3.9 (0.9)
Triglycerides, mmol/L� 1.3 (1.0) 1.4 (0.5)
Creatinine, μmol/L 115 (25) 122 (30)
Hemoglobin, g/L 12.4 (1.2) 12.3 (1.2)
hsCRP, mg/L ¤� 0.85 (2.20) 1.00 (1.19)
Calcium total, mmol/L 2.38 (0.09) 2.34 (0.21)
Phosphate, mmol/L � 0.9 (0.3) 0.8 (0.4)
Albumin, g/L 42.3 (2.5) 41.5 (2.4)
PTH, pmol/L � 10.1 (9.2) 10.2 (5.4)
Alkaline phosphatase, U/L 60.7 (21.8) 69.4 (28.6)
Vitamin 25-OH-D, nmol/l 50.1 (18.0) 44.8 (17.2)
Urine Albumin/creatinine ratio, mg/mmol � 3.1 (7.4) 4.5 (8.7)
BMI, body mass index; CKD, chronic kidney disease; HDL, high density lipoprotein; hsCRP, high-sensitive C-
reactive protein; LDL, low density lipoprotein; PTH, parathyroid hormone; ACEi, angiotensin converting enzyme
inhibitor; ARB, angiotensin receptor blocker.
All laboratory measurements are performed in plasma.
aModified version of table from the original publication [31]. Continuous data expressed as mean (standard
deviation) or � median (interquartile range).
Categorical data expressed as number (percentage frequency).
¤ Values <0.60mg/L (laboratory detection cut-off) are all given the value 0.30. Values >15mg/L are rounded down to
this value.
https://doi.org/10.1371/journal.pone.0243759.t001
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a lower baseline vitamin 25-OH-D (t-test, p = 0.16) in the control group. Twenty-eight patients
(38%), equally divided between study groups, had an immunological cause of end-stage renal
disease, e.g. glomerulonephritis.
Two patients were diagnosed with biopsy-proven antibody mediated rejection at 1-year fol-
low up, while four patients were being treated for acute cellular rejection at time of study inclu-
sion or earlier postoperatively. Two patients suffered a cellular rejection in the interval
between study visits. Seven patients suffered one or more infections needing systemic antibi-
otic treatment over the duration of the study. None of these participants have been excluded
from the primary efficacy analyses.
Effects of paricalcitol on serum levels of inflammatory markers
Paricalcitol did not significantly reduce the levels of measured inflammatory markers as com-
pared with no treatment. Table 2 presents intention-to-treat analyses, showing the mean (or
Table 2. Plasma levels of biomarkers at baseline and study end, by treatment group.
Biomarker(plasma
levels)



















0.74 (0.49) 0.69 (0.41) -6.8 0.67 (0.46) 0.72 (0.55) +7.5 0.478 (-0.57–0.27) 0.561 (-0.52–
0.29)
sCD14 (ng/ml) 1.57 (0.21) 1.57 (0.30) +0.0 1.58 (0.27) 1.52 (0.29) -3.8 0.383 (-0.08–0.21) 0.375 (-0.07–
0.19)
sCD163 (ng/ml) 441 (230) 547 (316) +24.0 467 (238) 512 (190) +9.6 0.241 (-42.3–166) 0.287 (-45.0–
150)
DLL1 (ng/ml) 8.88 (2.07) 9.73 (2.83) +9.6 9.62 (2.40) 9.85 (2.84) +2.4 0.212 (-0.37–1.62) 0.312 (-0.49–
1.51)
Endostatin (ng/ml) 99.1 (21.8) 93.4 (21.6) -5.8 108.7 (32.2) 103.0 (32.1) -5.2 0.908 (-9.9–11.2) 0.593 (-12.5–
7.2)
MMP9 (ng/ml) 99.8 (67.7) 74.4 (43.7) -25.4 77.4 (35.9) 79.7 (78.8) +2.3 0.058 (-56.3–0.95) 0.357 (-31.6–
11.5)
sTNFr1(ng/ml) 1.95 (0.67) 2.01 (0.91) +3.1 2.22 (0.78) 2.16 (0.79) -2.7 0.464 (-0.21–0.46) 0.809 (-0.29–
0.37)
Galectin-3 (ng/ml) 1.41 (0.56) 1.17 (0.55) -17.1 1.48 (0.57) 1.26 (0.44) -14.9 0.835 (-0.25–0.20) 0.543 (-0.24–
0.13)
NGAL (ng/ml) 282 (122) 312 (144) +10.6 287 (145) 305 (133) +6.5 0.735 (-52.0–73.3) 0.681 (-48.6–
73.9)
vWF in % of ref.
plasma�
82.5 (89.5) 57.1(37.0) -30.8 102.8 (118.3) 57.8 (58.6) -43.8 0.228 (-15.1–62.3) 0.215 (-8.6–
37.4)
ActivinA (ng/ml)� 344 (739) 323 (1075) -6.1 578 (910) 681 (873) +17.8 0.696 (-206–306) 0.778 (-227–
302)
OPG (ng/ml) 0.91 (0.37) 1.10 (0.44) +20.9 1.08 (0.53) 1.13 (0.52) +4.6 0.030 (0.01–0.26) 0.062 (-0.01–
0.24)




21.4 (18.5) 21.1 (13.8) +1.4 22.1 (13.7) 20.4 (11.4) +7.7 0.787 (-12.5–16.3) 0.169 (-2.2–
12.04)
Intention-to-treat population. T-test for difference in change and supplementary ANCOVA: p-values presented with corresponding confidence intervals (CI).
DLL1, delta like canonical Notch ligand 1; MMP9, matrix metalloprotease-9; sTNFR1, soluble tumor necrosis factor receptor-1; NGAL, neutrophil gelatinase-associated
lipocalin; vWF, von Willebrand factor; OPG, osteoprotegerin; TIMP-1, Tissue inhibitor of metalloproteinase 1.
Data expressed as mean (standard deviation) or � median (interquartile range).
Continuous data expressed as mean (standard deviation) or � median (interquartile range).
https://doi.org/10.1371/journal.pone.0243759.t002
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median) levels of inflammatory biomarkers in each group at 8 weeks and 1 year post trans-
plant, together with the changes from baseline to study end given in percent of baseline mean
(or median). T-test for likelihood of observing the reported results given no true group differ-
ence is presented with corresponding p-values and confidence interval for the absolute group
difference in change. MMP-9 levels decreased in the paricalcitol group, while it increased in
the control group, but the difference was not statistically significant (t-test for difference in
change [ng/ml], p = 0.058; CI -56.3–0.95). Paricalcitol treatment was, however, associated with
increased mean OPG levels, as opposed to nearly no change in the control group (t-test for dif-
ference in change [ng/ml], p = 0.030; CI 0.01–0.26). A few extreme values were responsible for
at least some of this difference (Fig 1). For all other parameters, p-values for differences in
changes were>0.1 and potential effect sizes were small (Table 2).
No significant correlation was found between change in osteoprotegerin and change in
PTH (Pearson’s Correlation test, p = 0.74). Sensitivity analyses using ANCOVA did not mate-
rially change results: p = 0.062 for difference between groups in OPG at 1-year adjusted for
baseline OPG level (rightmost column Table 2).
Analyses of the per-protocol population (n = 67) did not change results; p = 0.041 for
increase in OPG and p = 0.076 for reductions in MMP-9 with paricalcitol treatment (t-test, S1
Table). Results of sensitivity analyses excluding patients diagnosed with rejection at any time
Fig 1. Changes in levels of osteoprotegerin across the study period. Osteoprotegerin change (ng/nl) in patients
treated with paricalcitol vs patients receiving no extra treatment; median (horizontal line), interquartile range (blue
box), outlier (˚).
https://doi.org/10.1371/journal.pone.0243759.g001
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point during follow up (n = 67) were also comparable to the main analysis; p = 0.048 for
increase in OPG and p = 0.086 for reductions in MMP-9 (t-test, S2 Table). Exclusion of
patients with glomerulonephritis as cause of ESRD did not affect results; n = 46, OPG:
p = 0.054 and MMP-9: p = 0.018 (t-test, S2 Table).
Gene expression in renal graft tissue in response to paricalcitol
In renal graft tissue of patients treated with paricalcitol, there was a 21% higher expression of
TNFRSF11B, the gene coding for osteoprotegerin, compared with the control group (median
gene expression 0.808 vs 0.668; p = 0.026 by KS test). We detected no other significant differ-
ences in the expression of biomarker genes between patients treated with paricalcitol and con-
trols, as illustrated by the heat map (Fig 2). All microarray data are available at the Gene
Expression Omnibus (GEO) database; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE83486.
Discussion
We explored the potential effects of paricalcitol treatment during the first year after kidney
transplantation on a wide range of biomarkers reflecting several aspects of inflammatory
responses, but were unable to confirm clinically or statistically significant effects ameliorating
inflammation. Paricalcitol treatment did, however, increase circulating OPG levels.
Fig 2. Heat map of inflammatory marker gene expression levels in graft tissue. The expression of 15 genes coding for 13
inflammatory biomarkers in 30 treated patients (to the left) vs 30 patients in the control group (to the right). Darker color
indicates higher expression levels. Z-scores of duplicated genes in the array are averaged. Genes coding for proteins with different
nomenclature: ACVR1/ACVR1B/ ACVR1C, activin A receptor subunits; ANGPT2, angiopoietin-2; COL18A1, endostatin;
LCN2, neutrophil gelatinase-associated lipocalin (NGAL); LGALS3, galectin-3; TNFRSF11B, osteoprotegerin; TNFRSF1A,
soluble tumor necrosis factor receptor-1 (sTNFr1).
https://doi.org/10.1371/journal.pone.0243759.g002
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Importantly, this was accompanied by a corresponding increase in TNFRSF11b, the gene cod-
ing for OPG, in biopsies from renal allografts, supporting a link between paricalcitol and OPG.
The proposed anti-inflammatory effects of paricalcitol are ascribed to a regulatory role of
vitamin D receptor activation in several subsets of immune cells, such as macrophages, den-
dritic cells and T-cells [34, 35]. However, in one clinical study in patients with vascular inflam-
mation, paricalcitol appeared to exert its effect rather selectively on T-helper cells by
interfering with calcineurin-mediated responses [36]. Modulation of adaptive immune
responses in CKD-patients has been demonstrated, reflected by reductions in several inflam-
matory markers of Th1- Th2 and Th17-responses [37]. Oblak et al. [30] demonstrated treat-
ment effects in a quite large interventional study of RTRs. However, most clinical trials
suggesting anti-inflammatory properties of paricalcitol in CKD-patients [38–41] and RTRs
[42] has been hampered by a limited sample size. The adequately powered VITAL-study
(n = 281) failed to show significant effects of paricalcitol on inflammatory biomarkers (CRP,
fibrinogen, interleukin 6, TNF)in type 2 diabetes mellitus [25]. Taken together, the results of
interventional studies on vitamin D agonist treatment seem inconclusive.
In the present study we found no evidence of paricalcitol influencing markers reflecting
monocyte/macrophage (i.e. sCD163, sCD14, neopterin) or neutrophil (i.e. NGAL) activation,
which signals no major clinically beneficial effect of paricalcitol on the activation and interplay
of immune cells in the context of kidney transplantation. However, in light of recent findings
suggesting that paricalcitol modulates inflammatory responses by influencing the calcineurin-
axis [36], is it possible that anti-inflammatory effects could be masked by calcineurin inhibitor
treatment, the corner stone in the immunosuppressive regimen for all our study participants.
Paricalcitol appears also to reduce development of renal interstitial fibrosis in obstructive
nephropathy [43] and RTRs [44]. Metalloproteases, including MMP-9, are major regulators of
ECM protein metabolism [45]. One might be tempted to interpret the trend towards reduced
MMP-9 in paricalcitol-treated patients as a potential effect of VDRA on tissue extracellular matrix
(ECM) remodeling, but it remains a speculation. A major source of MMP-9 in the circulation is
neutrophils [46], hence plasma levels might also to some extent reflect neutrophil activation status.
We found that patients randomized to paricalcitol experienced an increase in circulating levels
of OPG not seen in the control group. Correspondingly, the expression of the gene TNFRSF11B
coding for OPG was also higher in renal graft tissue of patients in the intervention group. The
result is consistent with experimental data on the immunomodulatory effects of 1,25-hydroxyvita-
min D3 [47] and a similar clinical trial in hemodialysis patients [48]. Hansen et al. [48] found the
rise in OPG in patients treated with paricalcitol to be correlated with the degree of suppression of
PTH, partly explaining their results. Such a correlation was not clear in our cohort, despite a sig-
nificant PTH-lowering effect of paricalcitol [31]. OPG protects the skeleton from excessive bone
resorption by attaching to receptor activator of nuclear factor kappa-Β ligand (RANKL) and pre-
venting it from binding to its receptor on osteoclasts, RANK [49]. Plasma OPG has been sug-
gested as a stable marker of the general activity in the RANKL/RANK system, a system that is
linked to fibrogenesis and regulation of extracellular matrix. It is debated whether OPG itself is
cardioprotective or a reactive proinflammatory molecule [50, 51]but modulatory roles in vascular
injury and calcification, systemic inflammation and atherosclerosis, as well as in fibrosis pathways
have been suggested [52, 53]. Thus, together with the potential downregulation of MMP-9 the
effect seen on OPG may suggest that paricalcitol could have some effect on fibrogenesis in RTRs.
Interpretation of findings
Since inflammatory markers typically have a wide distribution and relatively large SD’s, the
power to detect group differences in a moderate-sized study, such as ours, could be lower than
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anticipated. As an example, MMP-9-levels were reduced by mean 25 ng/ml in the intervention
group, while the controls had a 2 ng/ml rise during the study period. However, a 45 ng/ml dif-
ference in treatment effect would be needed to claim statistical significance (p<0.05). This is a
high threshold for a biomarker whose reference range in healthy males is approximately 20–
100 (M ±2SD) ng/ml [54]. Effect sizes may be more relevant that any p-value in itself [55].
Thus, although significant p-values are lacking in the current study, our results should not be
interpreted as firm evidence against a potential anti-inflammatory effect of paricalcitol. Instead
our results signal possible small-to-moderate effects within the limits of the reported confi-
dence intervals. Taken together, evidence nevertheless seems too inconsistent to motivate the
routine use of VDRA to reduce inflammation or improve vascular health in the transplant
population. However, the interaction between paricalcitol and OPG as seen both at protein
and transcript levels should be further explored as a potential important target for VDRAs.
Also, though considered beyond the scope of the current investigation, the potential effect of
paricalcitol on markers of oxidative stress (e.g. lipid peroxidation metabolites), as well as
inflammatory metabolites (e.g. colonic microbiota-derived uraemic retention solutes) would
be an interesting focus for future studies.
Strengths and limitations
There was a high level of adherence to treatment in the paricalcitol group and no patient-initi-
ated withdrawals [31]. The study population has been well characterized. Both circulating bio-
marker levels and tissue biomarker gene expression were evaluated, thus increasing the
robustness of the results. However, sample size was calculated for the primary trial endpoint,
not for the detection of potential treatment effects on levels of inflammatory markers. Notably,
this study is of an explorative nature, testing many biomarkers at the same time. The suggested
association between VDRA and OPG must be interpreted with caution, due to the possibility
of making type 1-errors when performing multiple statistical tests. If strict Bonferroni correc-
tion for multiple testing was to be applied in this study, a p-value of<0,003 (0,05/15) would be
needed to demonstrate statistical significance. Conclusions drawn from this study might only
be valid for a white European population of RTRs with a reasonably good allograft function
(i.e. eGFR>30 ml/min). Results are not necessarily applicable for recipients with vitamin D
deficiency. We acknowledge that investigational bias might be a problem in open label trials,
but for administrative reasons placebo drugs were unfortunately not available.
Conclusions
In newly transplanted RTRs with adequate graft function, we were not able to demonstrate
convincing reductions in levels of circulating biomarkers of inflammation and endothelial
function after ten months of paricalcitol treatment. If present, a modulating effect of VDRA-
treatment on systemic inflammation in this patient group is likely to be modest. We found
that VDRA-treatment might increase levels of OPG, both in the circulation and in renal tissue,
but this result needs to be replicated and validated.
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